Genta Announces Top-Line Results Of AGENDA Phase 3 Trial Of Genasense(R) In Patients With Advanced Melanoma

Links shared publicly online about this topic.

  • 1,632
    total visits

Genta Announces Top-Line Results Of AGENDA Phase 3 Trial Of Genasense(R) In Patients With Advanced Melanoma

medicalnewstoday.com —

Genta Incorporated (OTCBB: GETA) announced top-line results from AGENDA, the Company's Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a

View full resource at medicalnewstoday.com

Tags: Cancer, Skin Cancer, Melanoma, Mineral, Sodium, Phase 3 Clinical Trial

  • Share

Most Recently Shared on November 2, 2009 at 3:37 pm By:

mnt_clinical MNT Clinical Trials

Genta Announces Top-Line Results Of AGENDA Phase 3 Trial Of Genasense(R) In Patients With Advanced Melanoma: Ge.. http://bit.ly/3L0RgJ

3 years ago...

Reply

Retweet

Favorite

Advertisement